Further research showed that DAA could release NRF2 after binding to KEAP1 and suppress ferroptosis via regulating the NRF2-ARE pathway, thus improving HFD-induced NAFLD [152]. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.